Dongguan Taili Biotech Co., Ltd. – Trademark Portfolio

Entity Type: 99

Dongguan Taili Biotech Co., Ltd. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 4 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include ALFACELL and ALFASTAX. The owner is based in Dongguan, Guangdong.

Tutang Village, Changping Town

Dongguan, Guangdong N/A , CN

4 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ALFACELL
ALFACELL
Registered 2021
ALFASTAX
ALFASTAX
Registered 2021
ALFAMEDX
ALFAMEDX
Abandoned 2020

Trademark Classifications

Dongguan Taili Biotech Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

42
Computer & Scientific (4 filings)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does Dongguan Taili Biotech Co., Ltd. have?

Dongguan Taili Biotech Co., Ltd. has 4 U.S. trademarks filed with the USPTO. Of these, 2 registered, 2 abandoned.

What trademark classes does Dongguan Taili Biotech Co., Ltd. file in?

Dongguan Taili Biotech Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 42 (Computer & Scientific). Class 42 covers scientific and technological services; industrial analysis and research services.

What are Dongguan Taili Biotech Co., Ltd.'s most well-known trademarks?

Dongguan Taili Biotech Co., Ltd.'s registered trademark portfolio includes well-known marks such as ALFACELL and ALFASTAX. These are among 2 currently registered trademarks in the portfolio.

What is Dongguan Taili Biotech Co., Ltd.'s trademark registration success rate?

Dongguan Taili Biotech Co., Ltd. has a 50% trademark registration rate, with 2 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.